TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,313.20▼ 0.75%TCS₹2,298.00▲ 2.08%HDFCBANK₹725.05▼ 6.76%ICICIBANK₹1,411.90▼ 3.31%INFY₹1,130.00▲ 3.95%HINDUNILVR₹2,028.00▼ 5.22%ITC₹271.65▼ 3.91%SBIN₹1,048.00▼ 1.13%BHARTIARTL₹1,941.70▼ 0.34%KOTAKBANK₹397.35▲ 4.00%LT₹4,081.00▲ 6.31%AXISBANK₹1,251.00▼ 0.40%ASIANPAINT₹2,625.20▼ 2.50%MARUTI₹13,809.00▲ 2.18%AAPL$317.61▼ 2.75%MSFT$481.14▲ 19.60%GOOGL$341.22▼ 3.06%AMZN$261.20▲ 4.48%NVDA$218.03▲ 7.26%META$544.51▼ 15.69%TSLA$341.10▼ 7.70%BRK-B$499.37▲ 1.65%JPM$357.57▲ 5.52%V$368.75▲ 2.27%
RELIANCE₹1,313.20▼ 0.75%TCS₹2,298.00▲ 2.08%HDFCBANK₹725.05▼ 6.76%ICICIBANK₹1,411.90▼ 3.31%INFY₹1,130.00▲ 3.95%HINDUNILVR₹2,028.00▼ 5.22%ITC₹271.65▼ 3.91%SBIN₹1,048.00▼ 1.13%BHARTIARTL₹1,941.70▼ 0.34%KOTAKBANK₹397.35▲ 4.00%LT₹4,081.00▲ 6.31%AXISBANK₹1,251.00▼ 0.40%ASIANPAINT₹2,625.20▼ 2.50%MARUTI₹13,809.00▲ 2.18%AAPL$317.61▼ 2.75%MSFT$481.14▲ 19.60%GOOGL$341.22▼ 3.06%AMZN$261.20▲ 4.48%NVDA$218.03▲ 7.26%META$544.51▼ 15.69%TSLA$341.10▼ 7.70%BRK-B$499.37▲ 1.65%JPM$357.57▲ 5.52%V$368.75▲ 2.27%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸AZN

AstraZeneca PLC Ordinary Shares

NYSE
$164.87
▲ $0.35 (+0.2%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 20 Aug 2026
H $212.71L $153.41-14.8%
$212.71$200.85$188.99$177.13$165.27$153.41$164.82
RSI (14)
Intraday · 15-minBuy+15RSI 59UptrendMACD Bearishfor day-trading context — not advice

Technical signal

Sell-35
RSI (14)49
oversold 30overbought 70
Trend
Downtrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
below
vs 200-day
below
Support
$153.41
Resistance
$175.04
  • Price is below its 50-day average (medium-term weakness).

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Signal backtest · 2025-11-12 → 2026-08-19

Strategy return
+1.5%
Buy & hold
-6.0%
Trades
5
Win rate
60%

$100,000.00 invested would be worth $101,464.79 (+1.5%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About AstraZeneca PLC· Drug Manufacturers - General

source: yahoo

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
96,100
Headquarters

Fundamentals

source: yahoo
Market cap
$255.7B
P/E
24.7
P/B
5.1
EPS
$6.68
Div yield
1.9%
Profit margin
17.0%
ROE
22.0%
Debt / Equity
0.64
Beta
0.21
52-week range
$145.80 – $212.71
52-week low · $145.8029% of rangehigh · $212.71

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive2↑ · 0↓ · 6–
  • The Key to Pharma M&A: Never Shopping Hungry— Neutral
    The Wall Street Journal · 19 Aug 2026
  • Pfizer's Obesity Push: Can Berobenatide Take Market Share?— Neutral
    Zacks · 19 Aug 2026
  • BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment▲ Positive
    Zacks · 19 Aug 2026
  • AstraZeneca (LSE:AZN) Reports Positive Phase III Lung Cancer Trial Results
Cambridge, United Kingdom
www.astrazeneca.com ↗
▲ Positive
Simply Wall St. · 19 Aug 2026
  • HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation— Neutral
    TMX Newsfile · 19 Aug 2026
  • Can AstraZeneca (LSE:AZN) Still Be A Bargain After Mixed Trial News?— Neutral
    Simply Wall St. · 19 Aug 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.